These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31157801)

  • 1. Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe Resolution.
    Scheepers HP; Langedijk J; Neerup Handlos V; Walser S; Schutjens MH; Neef C
    Eur J Hosp Pharm; 2017 Jul; 24(4):224-229. PubMed ID: 31157801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Council of Europe Resolution on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients.
    Scheepers HPA; Neerup Handlos V; Walser S; Schutjens MDB; Neef C
    Eur J Hosp Pharm; 2017 Jul; 24(4):218-223. PubMed ID: 31157793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe.
    Minghetti P; Pantano D; Gennari CG; Casiraghi A
    Health Policy; 2014 Sep; 117(3):328-33. PubMed ID: 25110297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aseptic preparation of parenteral medicinal products in healthcare establishments in Europe.
    Scheepers H; Beaney AM; Le Brun P; Neerup Handlos V; Schutjens M; Walser S; Neef C
    Eur J Hosp Pharm; 2016 Jan; 23(1):50-53. PubMed ID: 31156814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy of unlicensed medicines prepared and distributed by Dutch pharmacies.
    Scheepers H; Neerup Handlos V; Schutjens MH; Neef C
    Eur J Hosp Pharm; 2018 Nov; 25(6):344-348. PubMed ID: 31157057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Outlook on the European and Italian Rules to Guarantee Magistral Formulas.
    Selmin F; Casiraghi A; Musazzi UM; Fortini M; Minghetti P
    Int J Pharm Compd; 2019; 23(1):6-12. PubMed ID: 30668530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Council of Europe Resolution CM/Res(2016)2: a major contribution to patient safety from reconstituted injectable medicines?
    Beaney AM; Le Brun P; Ravera S; Scheepers H
    Eur J Hosp Pharm; 2020 Jul; 27(4):216-221. PubMed ID: 32587080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inspectorate surveillance of preparing and distributing pharmacies in The Netherlands.
    Scheepers HPA; Neerup Handlos V; Schutjens MH; Neef C
    Eur J Hosp Pharm; 2017 May; 24(3):147-151. PubMed ID: 31156926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Extent of Extemporaneous Preparation and Regulatory Framework of Extemporaneous Compounding in Latvia.
    Kiseļova O; Mauriņa B; Šidlovska V; Zvejnieks J
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31454896
    [No Abstract]   [Full Text] [Related]  

  • 14. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
    Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
    Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Market access for Chinese herbal medicinal products in Europe-A ten-year review of relevant products, policies, and challenges.
    Xiong Y; Li M; Sun P; Liang W; Hornbeck RG; Che X; Rao C; Zhao Y; Guo L; Huang Y; Yang H; Li P; Kroes BH; Cui X; Franz G; Wang M
    Phytomedicine; 2022 Aug; 103():154237. PubMed ID: 35688101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulations applicable to plant food supplements and related products in the European Union.
    Silano V; Coppens P; Larrañaga-Guetaria A; Minghetti P; Roth-Ehrang R
    Food Funct; 2011 Dec; 2(12):710-9. PubMed ID: 21997496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities and hurdles to European market access for multi-herbal traditional Chinese medicine products: An analysis of EU regulations for combination herbal medicinal products.
    Qu L; Li X; Xiong Y; Wang Z; Zhou Y; Zou W; Tang J; Wang M
    Pharmacol Res; 2022 Dec; 186():106528. PubMed ID: 36332812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.